Evidence map›Paper›PMID 22479556›Full record

ArticlePloS one2012

Tuberculosis in HIV-negative and HIV-infected patients in a low-incidence country: clinical characteristics and treatment outcomes.

Lukas Fenner, Sebastien Gagneux, Jean-Paul Janssens, Jan Fehr, Matthias Cavassini, Matthias Hoffmann, Enos Bernasconi, Jacques Schrenzel, Thomas Bodmer, Erik C Böttger and 3 more

Open access · goldAbstract read
In one paragraph

Article in PloS one, 2012. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 9 papers.

0numbers the graph read from it
0cells of the map it votes in
9citing papers in PubMed
1.8field-weighted citation impact, top 15% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

9 citing papers in PubMed, 17 citations in OpenAlex.

  1. Article
  2. Microorganisms · 2022
    Article
  3. Article
  4. Article
  5. Article
  6. Article
  7. Tuberculosis: epidemiology and control.Mediterranean journal of hematology and infectious diseases · 2014
    Review
  8. Article
  9. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

13 authors at 9 institutions in 1 country.

Lukas FennerInstitute of Social and Preventive Medicine (ISPM), University of Bern, Bern, Switzerland.
Sebastien Gagneux
Jean-Paul Janssens
Jan Fehr
Matthias Cavassini
Matthias Hoffmann
Enos Bernasconi
Jacques Schrenzel
Thomas Bodmer
Erik C Böttger
Peter Helbling
Matthias Egger
Swiss HIV Cohort and Molecular Epidemiology of Tuberculosis Study Groups
University Hospital of Geneva · CHUniversity of Bern · CHFederal Office of Public Health · CHInstitute of Social and Preventive Medicine · CHKantonsspital St. Gallen · CHOspedale regionale di Lugano · CHSwiss Tropical and Public Health Institute · CHUniversity Hospital of Zurich · CHUniversity of Zurich · CH

Funding

Observational Antiretroviral Studies In Southern Africa (OASIS) CollaborationU01AI069924 · NIAID · UNIVERSITAT BERN · PI Cleophas Chimbetete, Mary-Ann Davies · 2006 to 2026
$55.9M
Mycobacterium tuberculosis antigen diversityR01AI090928 · NIAID · NEW YORK UNIVERSITY SCHOOL OF MEDICINE · PI ERNST, JOEL D., GAGNEUX, SEBASTIEN · 2010 to 2014
$3.2M
NIAID NIH HHS 5U01-AI069924-5NIAID NIH HHS R01 AI090928NIAID NIH HHS R01-AI090928-01NIAID NIH HHS U01 AI069924
6 · The paper itself

Abstract

backgroundIn Switzerland and other developed countries, the number of tuberculosis (TB) cases has been decreasing for decades, but HIV-infected patients and migrants remain risk groups. The aim of this study was to compare characteristics of TB in HIV-negative and HIV-infected patients diagnosed in Switzerland, and between coinfected patients enrolled and not enrolled in the national Swiss HIV Cohort Study (SHCS). METHODS AND

findingsAll patients diagnosed with culture-confirmed TB in the SHCS and a random sample of culture-confirmed cases reported to the national TB registry 2000-2008 were included. Outcomes were assessed in HIV-infected patients and considered successful in case of cure or treatment completion. Ninety-three SHCS patients and 288 patients selected randomly from 4221 registered patients were analyzed. The registry sample included 10 (3.5%) coinfected patients not enrolled in the SHCS: the estimated number of HIV-infected patients not enrolled in the SHCS but reported to the registry 2000-2008 was 146 (95% CI 122-173). Coinfected patients were more likely to be from sub-Saharan Africa (51.5% versus 15.8%, P<0.0001) and to present disseminated disease (23.9% vs. 3.4%, P<0.0001) than HIV-negative patients. Coinfected patients not enrolled in the SHCS were asylum seekers or migrant workers, with lower CD4 cell counts at TB diagnosis (median CD4 count 79 cells/µL compared to 149 cells/µL among SHCS patients, P = 0.07). There were 6 patients (60.0%) with successful outcomes compared to 82 (88.2%) patients in the SHCS (P = 0.023).

conclusionsThe clinical presentation of coinfected patients differed from HIV-negative TB patients. The number of HIV-infected patients diagnosed with TB outside the SHCS is similar to the number diagnosed within the cohort but outcomes are poorer in patients not followed up in the national cohort. Special efforts are required to address the needs of this vulnerable population.

Indexed as

AdultCD4-Positive T-LymphocytesCohort StudiesComorbidityFemaleHIV InfectionsHIV SeropositivityHumansIncidenceMaleMiddle AgedProspective StudiesRiskSwitzerlandTransients and MigrantsTreatment Outcome

Identifiers

PMID22479556
PMCPMC3316631
OpenAlexW2100648030

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.